Sroka-Tomaszewska Jowita, Bulińska Barabara, Wilkowska Aleksandra, Nowicki Roman J, Trzeciak Magdalena
Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland.
Postepy Dermatol Alergol. 2023 Dec;40(6):747-752. doi: 10.5114/ada.2023.133818. Epub 2024 Jan 8.
Atopic dermatitis is a relapsing, chronic, inflammatory dermatosis. So far, treatment options for more severe forms of the disease have been limited. The prospect has changed with the advent of biological drug registrations. Dupilumab is a monoclonal antibody targeting the a subunit of the IL-4 receptor and is responsible for blocking the signalling of interleukin (IL) 4 (IL-4) and IL-13. Clinical trials conducted for over 10 years have confirmed the efficacy and safety of dupilumab's treatment for atopic dermatitis.
Evaluating the efficacy of dupilumab treatment in patients with moderate and severe atopic dermatitis in real life.
We retrospectively evaluated medical records of patients treated with dupilumab for atopic dermatitis at the Department of Dermatology, Venereology and Allergology in Gdansk.
Ten patients in total were studied. They received dupilumab with standard dosing. The mean percentage reduction in SCORAD score was 52.16% in 8 weeks. Dupilumab was generally well tolerated and did not cause serious side effects. The most common adverse event was conjunctivitis.
Dupilumab is an effective disease-modifying drug for patients with moderate to severe atopic dermatitis. The effects of treatment in real life are consistent with those demonstrated in clinical trials.
特应性皮炎是一种复发性、慢性炎症性皮肤病。到目前为止，针对该疾病更严重形式的治疗选择一直有限。随着生物药物注册的出现，这种前景已经改变。度普利尤单抗是一种靶向白细胞介素4（IL-4）受体α亚基的单克隆抗体，负责阻断白细胞介素（IL）4（IL-4）和IL-13的信号传导。超过10年的临床试验证实了度普利尤单抗治疗特应性皮炎的有效性和安全性。
评估度普利尤单抗在现实生活中治疗中度和重度特应性皮炎患者的疗效。
我们回顾性评估了在格但斯克皮肤病、性病和变态反应科接受度普利尤单抗治疗特应性皮炎患者的病历。
总共研究了10名患者。他们接受了标准剂量的度普利尤单抗治疗。8周内SCORAD评分的平均降低百分比为52.16%。度普利尤单抗总体耐受性良好，未引起严重副作用。最常见的不良事件是结膜炎。
度普利尤单抗是一种治疗中度至重度特应性皮炎患者的有效疾病改善药物。现实生活中的治疗效果与临床试验中证明的效果一致。
